Related Experiment Video
Updated: Oct 15, 2025
08:42
Application of a C. elegans Dopamine Neuron Degeneration Assay for the Validation of Potential Parkinson's Disease Genes
Published on: July 18, 2008
16.2K
The commercial genetic testing landscape for Parkinson's disease
Lola Cook1, Jeanine Schulze1, Jennifer Verbrugge1
1Department of Medical and Molecular Genetics (LC, JS, TF), Indiana University School of Medicine, Indianapolis, USA.
Parkinsonism & Related Disorders
|October 26, 2021
Summary
Clinical genetic testing for Parkinson's disease (PD) lacks standardized gene panels. A review found significant variation in gene content among 502 PD tests, highlighting the need for expert guidelines.
Area of Science:
- Genetics
- Neurology
- Clinical Diagnostics
Background:
- Clinical genetic testing for Parkinson's disease (PD) lacks established guidelines for gene selection.
- This variability impacts diagnostic accuracy and patient care.
Purpose of the Study:
- To evaluate the landscape of commercially available genetic tests for Parkinson's disease.
- To identify common and variable gene content in PD genetic panels.
Main Methods:
- A comprehensive query of the NIH Genetic Testing Registry (GTR) was performed on December 7, 2020.
- Identified 502 unique clinical genetic tests for PD offered by 28 CLIA-approved laboratories, including 11 diagnostic panels.
Main Results:
- PD genetic panels varied significantly in size (5-62 genes).
- Five core genes (SNCA, PRKN, PINK-1, PARK7, LRRK2) were consistently included.
- Inclusion of VPS35 and GBA genes was variable, and panels often contained genes linked to atypical parkinsonism or controversial PD associations.
Conclusions:
- There is an urgent need for expert consensus on recommended genes for commercial Parkinson's disease multi-gene panels.
- Standardization would improve the reliability and utility of genetic testing for PD.
More Related Videos
Related Concept Videos
01:15Parkinson's Disease: Overview
832
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
832
01:24Parkinson's Disease: Treatment
441
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
441
01:11Genome-wide Association Studies-GWAS
14.7K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
14.7K